131 related articles for article (PubMed ID: 36672477)
21. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
22. Density and location of CD3
Zhou C; Wu Y; Jiang L; Li Z; Diao P; Wang D; Zhang W; Liu L; Wang Y; Jiang H; Cheng J; Yang J
J Oral Pathol Med; 2018 Apr; 47(4):359-367. PubMed ID: 29469989
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis.
Hao J; Yu H; Zhang T; An R; Xue Y
Ther Adv Med Oncol; 2020; 12():1758835920967241. PubMed ID: 33193829
[TBL] [Abstract][Full Text] [Related]
24. Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
Kono-Sato T; Miyai K; Yamagishi Y; Miyamoto M; Takano M; Matsukuma S; Sato K; Tsuda H
BMC Cancer; 2022 Apr; 22(1):361. PubMed ID: 35366828
[TBL] [Abstract][Full Text] [Related]
25. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
[TBL] [Abstract][Full Text] [Related]
26. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
27. Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC.
Pateras IS; Kotsakis A; Avgeris M; Baliou E; Kouroupakis P; Patsea E; Georgoulias V; Menez-Jamet J; Kinet JP; Kosmatopoulos K
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916194
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
29. CD3 high and FoxP3 - tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder.
Sun ZJ; Zhao JW; Zhao M; Chen Y; Zhang X; Li HC; Wu GQ; Zhang DH
Anticancer Drugs; 2023 Aug; 34(7):844-851. PubMed ID: 36563023
[TBL] [Abstract][Full Text] [Related]
30. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract][Full Text] [Related]
31. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
33. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
34. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
Front Oncol; 2020; 10():314. PubMed ID: 32232003
[No Abstract] [Full Text] [Related]
35. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract][Full Text] [Related]
37. The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.
Jääskeläinen MM; Tiainen S; Siiskonen H; Ahtiainen M; Kuopio T; Rönkä A; Kettunen T; Hämäläinen K; Rilla K; Harvima I; Mannermaa A; Auvinen P
Breast Cancer Res Treat; 2023 Sep; 201(2):183-192. PubMed ID: 37428418
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.
Liu W; Chen G; Zhang C; Liao X; Xie J; Liang T; Liao W; Song L; Zhang X
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):25-35. PubMed ID: 34027599
[TBL] [Abstract][Full Text] [Related]
39. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
Front Oncol; 2022; 12():816706. PubMed ID: 35321431
[TBL] [Abstract][Full Text] [Related]
40. Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
Ono A; Terada Y; Kawata T; Serizawa M; Isaka M; Kawabata T; Imai T; Mori K; Muramatsu K; Hayashi I; Kenmotsu H; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Akiyama Y; Sugino T; Ohde Y; Yamaguchi K; Takahashi T
Cancer Med; 2020 Jul; 9(13):4864-4875. PubMed ID: 32400056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
